Flexible Dosing Options
Extend up to Q16 dosing directly after only 3 loading doses in both nAMD and DME with EYLEA 8mg


The frequency of monitoring visits should be based on the patient’s status and at the physician’s discretion.
Dosing diagram for illustrative purpose only.
After reaching Q16, patients can be extended to Q24 using an extension method such as T&E*
The flexibility to use your clinic's extension method, such as T&E.


The frequency of monitoring visits should be based on the patient’s status and at the physician’s discretion.
Dosing diagram for illustrative purpose only.
* Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q24 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.
The recommended dose is 8mg aflibercept, equivalent to 0.07 mL solution. The posology is the same for the nAMD and DME indications. The 8mg dose requires use of the EYLEA 114.3 mg/ml pre-filled syringe.
EYLEA PFS at monthly doses of 8mg has not been studied for more than 3 consecutive doses.
EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME).
Abbreviations
PP-EYL_8mg-IE-0159-1 | January 2026
